Finance

Beta
Lists
543904:BOM
Mankind Pharma Ltd
₹2,491.45
-2.10%
(-53.55) 1D
Jul 17, 3:59:41 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 543904...
Open
₹2,560.60
High
₹2,560.60
Low
₹2,471.00
Mkt. cap
1.03T
Avg. vol.
28.93K
Volume
71.92K
Dividend
0.04%
Quarterly dividend
₹0.25
Ex-dividend date
Aug 8, 2025
P/E ratio
53.83
52-wk high
₹2,706.60
52-wk low
₹1,909.90
EPS
₹46.28
No. of employees
20K
Open
₹2,560.60
High
₹2,560.60
Low
₹2,471.00
Mkt. cap
1.03T
Avg. vol.
28.93K
Volume
71.92K
Dividend
0.04%
Quarterly dividend
₹0.25
Ex-dividend date
Aug 8, 2025
P/E ratio
53.83
52-wk high
₹2,706.60
52-wk low
₹1,909.90
EPS
₹46.28
No. of employees
20K
News stories
From sources across the web
Profile
Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications. As of 2023, Mankind Pharma had 25 factories and 6 R&D centres in India. The company derived 97% of its operating revenue from the Indian market, where it is reportedly the fourth largest pharmaceutical company by domestic sales. Some of Mankind Pharma's consumer healthcare brands are the largest-selling in their respective categories, including Manforce in condoms, Prega News in pregnancy test kits, and Unwanted-72 in emergency contraception. Wikipedia
About Mankind Pharma Ltd
CEORajeev Juneja | Sheetal Arora
Employees20.5K
Founded1991
Headquarters-
SectorPharmaceutical industry
Websitemankindpharma.com
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
35.70B
36.97B
35.67B
34.43B
Cost of goods sold
10.54B
10.62B
9.78B
11.71B
Cost of revenue
10.54B
10.62B
9.78B
11.71B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.83B
8.25B
8.24B
15.80B
Operating expense
18.89B
19.35B
18.92B
14.77B
Total operating expenses
29.42B
29.98B
28.70B
26.48B
Operating income
6.28B
7.00B
6.97B
7.95B
Other non operating income
798.80M
918.70M
727.50M
-2.31B
EBT including unusual items
5.40B
6.24B
5.09B
6.59B
EBT excluding unusual items
5.40B
6.24B
6.16B
5.59B
Income tax expense
958.70M
1.04B
951.20M
997.50M
Effective tax rate
17.74%
16.64%
18.69%
15.13%
Other operating expenses
8.87B
8.88B
8.46B
-3.26B
Net income
4.38B
5.12B
4.09B
5.54B
Net profit margin
12.28%
13.84%
11.46%
16.10%
Earnings per share
10.60
12.38
11.99
13.89
Interest and investment income
-
-
-
580.50M
Interest expense
-1.71B
-1.70B
-1.57B
-1.36B
Net interest expenses
-1.71B
-1.70B
-1.57B
-778.20M
Depreciation and amortization charges
2.19B
2.22B
2.23B
2.23B
EBITDA
7.74B
9.20B
8.42B
9.97B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer